Editorial: Ferroptosis as a novel therapeutic target for inflammation-related diseases

Yongyi Liang; Zhenyi Su; Xiaoyuan Mao; Shibiao Wan; Lianxiang Luo

doi:10.3389/fphar.2023.1152326

Editorial: Ferroptosis as a novel therapeutic target for inflammation-related diseases

Front Pharmacol. 2023 Feb 16:14:1152326. doi: 10.3389/fphar.2023.1152326. eCollection 2023.

Authors

Yongyi Liang¹, Zhenyi Su², Xiaoyuan Mao³, Shibiao Wan⁴, Lianxiang Luo^{5

6}

Affiliations

¹ The First Clinical College, Guangdong Medical University, Zhanjiang, China.
² Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, United States.
³ Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
⁴ Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE, United States.
⁵ The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, China.
⁶ The Marine Biomedical Research Institute of Guangdong Zhanjiang, Zhanjiang, China.

No abstract available

Keywords: ferroptosis; immunomodulatory; inflammation-related diseases; inflammatory mediators; lipid peroxidation.

Publication types

Editorial

Grants and funding

This work was supported by the Buffet Cancer Center, which is supported by the National Cancer Institute under award number CA036727, in collaboration with the UNMC/Children’s Hospital & Medical Center Child Health Research Institute Pediatric Cancer Research Group.